Stock XSNX NOVACCESS GLOBAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials NovAccess Global Inc.

Equities

XSNX

US67001N1072

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 02:32:55 2024-05-03 pm EDT 		5-day change 1st Jan Change
0.0065 USD 0.00% Intraday chart for NovAccess Global Inc. +27.45% -67.66%
Apr. 29 NovAccess Global Inc. announced that it has received $0.0265 million in funding from AJB Capital Investments LLC CI
Feb. 27 NovAccess Global Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI

Valuation

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Capitalization 1 1.615 0.8009 6.371 6.686 2.24 2.174
Enterprise Value (EV) 1 1.815 1.014 6.682 6.896 3.652 4.534
P/E ratio -0.38 x 1 x -0.17 x -2.08 x -1.16 x -0.43 x
Yield - - - - - -
Capitalization / Revenue 2.43 x 0.5 x - - - -
EV / Revenue 2.73 x 0.63 x - - - -
EV / EBITDA -8.98 x 4.88 x -8.07 x - - -
EV / FCF 0.52 x -0.44 x 6.1 x 44.3 x -5.22 x 2.7 x
FCF Yield 193% -226% 16.4% 2.26% -19.2% 37.1%
Price to Book -0.35 x -0.36 x -0.13 x -0.74 x -0.24 x -0.17 x
Nbr of stocks (in thousands) 1,468 1,602 9,102 14,404 18,670 21,744
Reference price 2 1.100 0.5000 0.7000 0.4642 0.1200 0.1000
Announcement Date 1/7/19 12/20/19 3/30/21 1/13/22 1/10/23 2/9/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net sales 1 0.665 1.609 - - - -
EBITDA 1 -0.202 0.2079 -0.8283 - - -
EBIT 1 -0.2023 0.2073 -0.8289 -2.699 -1.368 -2.467
Operating Margin -30.42% 12.88% - - - -
Earnings before Tax (EBT) 1 -3.969 2.344 -6.991 -2.512 -1.716 -4.769
Net income 1 -3.969 2.344 -6.77 -2.512 -1.716 -4.769
Net margin -596.89% 145.7% - - - -
EPS 2 -2.932 0.5000 -4.222 -0.2231 -0.1038 -0.2300
Free Cash Flow 1 3.508 -2.294 1.096 0.1555 -0.7 1.68
FCF margin 527.46% -142.61% - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 1/7/19 12/20/19 3/30/21 1/13/22 1/10/23 2/9/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net Debt 1 0.2 0.21 0.31 0.21 1.41 2.36
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -0.9901 x 1.026 x -0.3756 x - - -
Free Cash Flow 1 3.51 -2.29 1.1 0.16 -0.7 1.68
ROE (net income / shareholders' equity) 140% -68.2% 241% 67% 40% 76.6%
ROA (Net income/ Total Assets) -125% 70.1% -481% -1,620% -513% -1,648%
Assets 1 3.178 3.342 1.407 0.1551 0.3343 0.2895
Book Value Per Share 2 -3.160 -1.400 -5.400 -0.6300 -0.5000 -0.5800
Cash Flow per Share 2 0.0300 0 0 0.0100 0 0
Capex - 0 - - - -
Capex / Sales - 0.14% - - - -
Announcement Date 1/7/19 12/20/19 3/30/21 1/13/22 1/10/23 2/9/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NOVACCESS GLOBAL INC. Stock NovAccess Global Inc.
-67.66% 227K
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.86B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.66B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. XSNX Stock
  4. Financials NovAccess Global Inc.